NEW YORK, May 1, 2024 /PRNewswire/ -- Traverse Biotech,
Inc. has been awarded a Phase I Small Business Innovation Research
(SBIR) grant from the National Institute of Allergy and Infectious
Diseases (NIAID), part of the NIH. This grant will support the
development of our oral innate immunotherapy stimulant modality
with an emphasis on the evaluation of monocytic cellular activation
using pathogen-associated molecular patterns (PAMPs) motifs.
Brandy Houser, co-Founder and CEO
of Traverse Biotech, expressed: "We are grateful for the support of
NIAID. We believe that our product candidate has broad
applicability to several immunological pathologies where myeloid
derived cells are dysfunctional and ultimately not effective in
disease resolution."
This work will be conducted in collaboration with Dr.
Sara Lustigman, Head of Molecular
Parasitology at Lindsley F. Kimball Research Institute of New York
Blood Center Enterprises. Dr. Lustigman's extensive academic
research in immunology and infectious diseases will enable the
evaluation of Traverse's innate immune stimulator mechanism of
action in validated preclinical pathogenic models.
About Traverse Biotech, Inc. is a privately held
US biotechnology company that develops innovative immunotherapy
products. Traverse Biotech focuses on late-stage preclinical and
early clinical development of product candidates derived from
de-risked technology platforms. For each product within its
pipeline, Traverse licenses worldwide commercialization rights from
selected international biopharma companies that are divesting
promising product candidates due to strategic portfolio
rationalization. Via an original partnership model, Traverse
Biotech accelerates therapeutic development of each asset through
clinical proof-of-concept. Its flexible and lean operating
structure enables rapid clinical evaluation and cost reduction
around all aspects of product development reaching patients
sooner.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/traverse-biotech-awarded-phase-i-sbir-grant-by-the-national-institute-of-allergy-and-infectious-diseases-for-development-of-innate-immune-stimulator-302132382.html
SOURCE Traverse Biotech